- Home
- PRLD vs OPRX Comparison
PRLD vs OPRX Comparison
Compare PRLD & OPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- OPRX
- Stock Information
- Founded
- PRLD 2016
- OPRX 2006
- Country
- PRLD United States
- OPRX United States
- Employees
- PRLD N/A
- OPRX N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- OPRX Business Services
- Sector
- PRLD Health Care
- OPRX Consumer Discretionary
- Exchange
- PRLD Nasdaq
- OPRX Nasdaq
- Market Cap
- PRLD 73.7M
- OPRX 84.4M
- IPO Year
- PRLD 2020
- OPRX N/A
- Fundamental
- Price
- PRLD $0.68
- OPRX $7.75
- Analyst Decision
- PRLD Strong Buy
- OPRX Buy
- Analyst Count
- PRLD 2
- OPRX 8
- Target Price
- PRLD $4.50
- OPRX $9.06
- AVG Volume (30 Days)
- PRLD 272.4K
- OPRX 1.3M
- Earning Date
- PRLD 05-06-2025
- OPRX 05-13-2025
- Dividend Yield
- PRLD N/A
- OPRX N/A
- EPS Growth
- PRLD N/A
- OPRX N/A
- EPS
- PRLD N/A
- OPRX N/A
- Revenue
- PRLD $7,000,000.00
- OPRX $92,127,000.00
- Revenue This Year
- PRLD N/A
- OPRX $12.12
- Revenue Next Year
- PRLD N/A
- OPRX $10.87
- P/E Ratio
- PRLD N/A
- OPRX N/A
- Revenue Growth
- PRLD N/A
- OPRX 28.81
- 52 Week Low
- PRLD $0.63
- OPRX $3.78
- 52 Week High
- PRLD $6.80
- OPRX $14.13
- Technical
- Relative Strength Index (RSI)
- PRLD 41.40
- OPRX 52.43
- Support Level
- PRLD $0.71
- OPRX $7.98
- Resistance Level
- PRLD $0.76
- OPRX $8.94
- Average True Range (ATR)
- PRLD 0.07
- OPRX 0.77
- MACD
- PRLD 0.01
- OPRX -0.15
- Stochastic Oscillator
- PRLD 18.75
- OPRX 24.55
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About OPRX OptimizeRx Corporation
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.